The Effect Of Public Markets On Manufacturing Cell & Gene Therapies

The manufacturing challenges that typify cell and gene therapy production are diverse, particularly where they intersect with public markets. From deciding when to scale up to whether to outsource and everything in between, the impact of external market forces on an advanced therapy’s timeline, commercial roadmap, and ultimate success makes understanding the greater public market crucial for drug developers and manufacturers.

The impact of market trends on biopharmaceutical companies varies widely, influenced by factors such as a company’s own market standing, whether it plans to outsource its manufacturing or produce in-house, or if it needs its own facilities or equipment. Approaching these variables with a nuanced understanding of the current market can help companies engage in informed decision making, better positioning them to scale in the face of external challenges affecting the sector more broadly.

In a recent webinar, “Public Markets’ Impact on Manufacturing Advanced Therapies,” an array of experts from across the cell and gene therapy space convened to explore how to ensure commercial viability for cell and gene therapy through the right approach to manufacturing. The webinar, sponsored by Project Farma and Precision ADVANCE, touched on public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. The panel of experts discussed their organizations' pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.